Topic: NR2A

Despite extensive research, effective treatment for Alzheimer’s disease (AD) remains elusive. Emerging evidence suggests that the endocannabinoid system and glutamatergic neurotransmission play important roles in AD pathophysiology. This project aims to elucidate the involvement of cannabinoid type 1 receptor (CB1R) on regulating the cytotoxic effects induced by N-methyl-D-aspartate receptors (NMDARs) in AD. On the one hand, CB1R activation reduces neuroinflammation and promotes neuroprotection in AD models. On the other hand, the synaptic receptor NR2A contribute to synaptic integrity and mem

Diabetes is a progressive metabolic disease that can severely damage several organs, including the central nervous system. It has been suggested that diabetes can induce cognitive dysfunction due to expression changes of excitatory neurotransmission mediated by N-methyl-D-aspartate (NMDA) receptors. In addition, diabetes is associated with imbalances in the regulation of intracellular Ca2+, which leads to neuronal damage and, ultimately, a decline in cognitive abilities. Moreover, Type 1 diabetes patients have higher glutamate levels in their brains, which can be used as an early marker of dia